Serum Soluble TWEAK Concentration is Decreased in Patients with Hepatocellular Cancer and Low Blood Levels of sTWEAK are Associated with Poor Survival

ASİL, Mehmet; Dertli, Ramazan

Serum Soluble TWEAK Concentration is Decreased in Patients with Hepatocellular Cancer and Low Blood Levels of sTWEAK are Associated with Poor Survival

Mehmet ASİL, (Necmettin Erbakan University, Meram Faculty of Medicine, Department of Gastroenterology, Konya, TURKEY)

Ramazan DERTLİ (Necmettin Erbakan University, Meram Faculty of Medicine, Department of Gastroenterology, Konya, TURKEY)

Uluslararası Hematoloji-Onkoloji Dergisi

4 0

Yıl: 2017 Cilt: 27 Sayı: 2 Sayfa Aralığı: 118 - 126 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Serum Soluble TWEAK Concentration is Decreased in Patients with Hepatocellular Cancer and Low Blood Levels of sTWEAK are Associated with Poor Survival

Öz:

Kötü Sağkalımla İlişkilidirTumor necrosis factor-like weak inducer of apoptosis (TWEAK) tümör nekrozis factor ailesinin bir üyesidir ve birçok kanserin patogenezinde rol oynadığı öne sürülmüştür. Bu çalışmada hepatoselüler kanser (HCC) hastalarında serum sTWEAK düzeylerinin araştırılması amaçlanmıştır. Yirmi sekiz HCC hastası, 28 siroz hastası ve 30 sağlıklı kontrol çalışmaya dahil edilerek serum sTWEAK konsantrasyonları ELISA yöntemiyle hazır kitler kullanılarak çalışılmıştır. HCC, siroz ve sağlıklı kontrol gruplarında ortalama serum sTWEAK konsantrasyonları 174.0±69.9 pg/ml, 221.4±61.2 pg/ml ve 288.0±68.4 pg/ml olup gruplar arasındaki fark istatistiksel olarak anlamlıydı (p< 0.001). HCC grubundaki ortalama sTWEAK konsantrasyonunun gerek siroz (p= 0.009) gerek de sağlıklı kontrol (p< 0.001) gruplarından daha düşük olduğu görüldü. ROC analizinde, sTWEAK için 1 yıllık mortaliteyi öngörme açısından eğri altında kalan alan 0.836 (%95CI: 0.684-0.987) ve belirlenen148,1 pg/ml eşik değeri için duyarlılık ve özgüllük %66.7 ve %92.3 olarak bulundu. Kaplan-Meier sağkalım analizi ile serum sTWEAK konsantrasyonu < 148,1 pg/ml olan hastalarda 1 yıllık sağkalım hızının anlamlı olarak daha düşük olduğu görüldü (log-rank testi, ?2= 11.75, p= 0.001). Cox regresyon analizinde de serum sTWEAK konsantrasyonunun mortaliteyi öngören bağımsız bir risk faktörü olduğu görüldü (Hazard oranı= 4.325, %95 CI: 1.080-17.326, p= 0.025). HCC hastalarında serum sTWEAK konsantrasyonu azalmıştır. Düşük serum sTWEAK düzeyleri, HCC hastalarında kötü prognoz ve yüksek bir yıllık mortalite oranlarıyla ilişkilidir

Anahtar Kelime:

Konular: Onkoloji

Serum Solubl TWEAK Konsantrasyonu Hepatoselüler Kanser Hastalarında Azalmıştır ve Düşük Kan sTWEAK Düzeyleri Kötü Sağkalımla İlişkilidir

Öz:

Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) is a member of the tumor necrosis factor superfamily and has been implicated in the pathogenesis of several cancers. This study was conducted to investigate serum sTWEAK levels and its relation with prognosis in patients with hepatocellular carcinoma (HCC). Twenty-eight cirrhotic patients with HCC, 28 patients with cirrhosis and 30 healthy subjects were included in the study. Serum sTWEAK concentrations were measured by using commercially available enzyme-linked immune sorbent assay kits. Mean serum sTWEAK concentrations in HCC, cirrhosis and healthy control groups were 174.0±69.9 pg/ml, 221.4±61.2 pg/ml and 288.0±68.4 pg/ml respectively and the difference between the groups was statistically significant (p< 0.001). Mean sTWEAK concentration in the HCC group was significantly lower than both cirrhosis group (p= 0.009) and healty controls (p< 0.001). In the ROC curve analysis, AUC for serum TWEAK concentration to predict one-year mortality in HCC patients was 0.836 (95% CI: 0.684-0.987) and for the specified cut-off value of 148.1 pg/ml, sensitivity and specificity were 66.7% and 92.3% respectively. Kaplan-Meier survival estimates showed that, survival rate was significantly lower in patients with serum sTWEAK< 148.1 pg/ml (log-rank test, χ2= 11.75, p= 0.001). Serum sTWEAK concentration was identified as an independent predictor of mortality in Cox regression analysis (Hazard ratio= 4.325, 95% CI: 1.080-17.326, p= 0.025). Serum sTWEAK concentration is decreased in HCC patients. Lower serum sTWEAK concentrations at the time of diagnosis are associated with poor prognosis and higher one-year mortality rates in HCC patients

Anahtar Kelime:

Konular: Onkoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893- 2917, 2010.
2. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 379: 1245-1255, 2012.
3. Burkly LC, Michaelson JS, Hahm K, et al. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine 40: 1-16, 2007.
4. Lassen UN, Meulendijks D, Siu LL, et al. A phase I monotherapy study of RG7212, a first-in-class monoclonal antibody targeting TWEAK signaling in patients with advanced cancers. Clin Cancer Res 21: 258-266, 2015.
5. Whitsett TG, Cheng E, Inge L, et al. Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion. Am J Pathol 181: 111-120, 2012.
6. Dai L, Gu L, Ding C, et al. TWEAK promotes ovarian cancer cell metastasis via NF-kappa B pathway activation and VEGF expression. Cancer Lett 283: 159-167, 2009.
7. Lin BR, Huang MT, Chen ST, et al. Prognostic significance of TWEAK expression in colorectal cancer and effect of its inhibition on invasion. Ann Surg Oncol 19 Suppl 3: S385-394, 2012.
8. Kwon OH, Park SJ, Kang TW, et al. Elevated fibroblast growth factor-inducible 14 expression promotes gastric cancer growth via nuclear factor-kappa B and is associated with poor patient outcome. Cancer Lett 314: 73-81, 2012.
9. Yin X, Luistro L, Zhong H, et al. RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response Clin Cancer Res 19: 5686-5698, 2013.
10. Lozano-Bartolomé J, Llauradó G, Rodriguez MM, et al. Reduced circulating levels of sTWEAK are associated with NAFLD and may affect hepatocyte triglyceride accumulation. Int J Obes (Lond) 40: 1337-1345.
11. Asil M, Dertli R. Serum soluble TWEAK levels are decreased in treatment naive noncirrhotic chronic hepatitis B patients. Medicine (Baltimore) 95: e4763, 2016.
12. Li N, Hu WJ, Shi J, et al. Roles of fibroblast growth factorinducible 14 in hepatocellular carcinoma. Asian Pac J Cancer Prev 14: 3509-3514, 2013.
13. Okuda K, Ohtsuki T, Obata H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56: 918-928, 1985.
14. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19: 329-338, 1999.
15. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334: 693-699, 1996.
16. Fan WC, Huang CC, Yang YY, et al. Serum pentraxin-3 and tumor necrosis factor-like weak inducer of apoptosis (TWEAK) predict severity of infections in acute decompensated cirrhotic patients. J Microbiol Immunol Infect 2016, doi:10.1016/j. jmii.2015.12.006.
17. Feng SL, Guo Y, Factor VM, et al. The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol 156: 1253-1261, 2000.
18. Aronin A, Amsili S, Prigozhina TB, et al. Fn14•TRAIL effectively inhibits hepatocellular carcinoma growth. PLoS One 8: e77050, 2013.
19. Turkmen K, Tonbul HZ, Erdur FM, et al. Soluble TWEAK independently predicts atherosclerosis in renal transplant patients. BMC Nephrol 14: 144, 2013.
20. Beltrán LM, Muñoz Hernández R, de Pablo Bernal RS, et al. Reduced sTWEAK and increased sCD163 levels in HIV-infected patients: modulation by antiretroviral treatment, HIV replication and HCV co-infection. PLoS One 9: e90541, 2014.
21. Asil M, Dertli R, Biyik M, et al. Non-alkolik steatohepatit, basit karaciger yaglanmasi hastalari ve saglikli kontrollerde serum soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) düzeyleri. 33. National Gastroenterology Week (33. Ulusal Gastroenteroloji Haftasi), Antalya, November 22-27, 2016: S-010.
22. Burkly LC, Michaelson JS, Zheng TS. TWEAK/Fn14 pathway: an immunological switch for shaping tissue responses. Immunol Rev 244: 99-114, 2011. 126 UHOD Number: 2 Volume: 27 Year: 2017 International Journal of Hematology and Oncology
23. Jakubowski A, Ambrose C, Parr M, et al. TWEAK induces liver progenitor cell proliferation. J Clin Invest 115: 2330-2340, 2005.
24. Avilés-Jurado FX, Terra X, Gómez D, et al. Low blood levels of sTWEAK are related to locoregional failure in head and neck cancer. Eur Arch Otorhinolaryngol 272: 1733-1741, 2015.
25. Terra X, Gómez D, García-Lorenzo J, et al. External validation of sTWEAK as a prognostic noninvasive biomarker for head and neck squamous cell carcinoma. Head Neck 38 Suppl 1: E1358-63, 2016.

APA	ASİL M, Dertli R (2017). Serum Soluble TWEAK Concentration is Decreased in Patients with Hepatocellular Cancer and Low Blood Levels of sTWEAK are Associated with Poor Survival. , 118 - 126.
Chicago	ASİL Mehmet,Dertli Ramazan Serum Soluble TWEAK Concentration is Decreased in Patients with Hepatocellular Cancer and Low Blood Levels of sTWEAK are Associated with Poor Survival. (2017): 118 - 126.
MLA	ASİL Mehmet,Dertli Ramazan Serum Soluble TWEAK Concentration is Decreased in Patients with Hepatocellular Cancer and Low Blood Levels of sTWEAK are Associated with Poor Survival. , 2017, ss.118 - 126.
AMA	ASİL M,Dertli R Serum Soluble TWEAK Concentration is Decreased in Patients with Hepatocellular Cancer and Low Blood Levels of sTWEAK are Associated with Poor Survival. . 2017; 118 - 126.
Vancouver	ASİL M,Dertli R Serum Soluble TWEAK Concentration is Decreased in Patients with Hepatocellular Cancer and Low Blood Levels of sTWEAK are Associated with Poor Survival. . 2017; 118 - 126.
IEEE	ASİL M,Dertli R "Serum Soluble TWEAK Concentration is Decreased in Patients with Hepatocellular Cancer and Low Blood Levels of sTWEAK are Associated with Poor Survival." , ss.118 - 126, 2017.
ISNAD	ASİL, Mehmet - Dertli, Ramazan. "Serum Soluble TWEAK Concentration is Decreased in Patients with Hepatocellular Cancer and Low Blood Levels of sTWEAK are Associated with Poor Survival". (2017), 118-126.

APA	ASİL M, Dertli R (2017). Serum Soluble TWEAK Concentration is Decreased in Patients with Hepatocellular Cancer and Low Blood Levels of sTWEAK are Associated with Poor Survival. Uluslararası Hematoloji-Onkoloji Dergisi, 27(2), 118 - 126.
Chicago	ASİL Mehmet,Dertli Ramazan Serum Soluble TWEAK Concentration is Decreased in Patients with Hepatocellular Cancer and Low Blood Levels of sTWEAK are Associated with Poor Survival. Uluslararası Hematoloji-Onkoloji Dergisi 27, no.2 (2017): 118 - 126.
MLA	ASİL Mehmet,Dertli Ramazan Serum Soluble TWEAK Concentration is Decreased in Patients with Hepatocellular Cancer and Low Blood Levels of sTWEAK are Associated with Poor Survival. Uluslararası Hematoloji-Onkoloji Dergisi, vol.27, no.2, 2017, ss.118 - 126.
AMA	ASİL M,Dertli R Serum Soluble TWEAK Concentration is Decreased in Patients with Hepatocellular Cancer and Low Blood Levels of sTWEAK are Associated with Poor Survival. Uluslararası Hematoloji-Onkoloji Dergisi. 2017; 27(2): 118 - 126.
Vancouver	ASİL M,Dertli R Serum Soluble TWEAK Concentration is Decreased in Patients with Hepatocellular Cancer and Low Blood Levels of sTWEAK are Associated with Poor Survival. Uluslararası Hematoloji-Onkoloji Dergisi. 2017; 27(2): 118 - 126.
IEEE	ASİL M,Dertli R "Serum Soluble TWEAK Concentration is Decreased in Patients with Hepatocellular Cancer and Low Blood Levels of sTWEAK are Associated with Poor Survival." Uluslararası Hematoloji-Onkoloji Dergisi, 27, ss.118 - 126, 2017.
ISNAD	ASİL, Mehmet - Dertli, Ramazan. "Serum Soluble TWEAK Concentration is Decreased in Patients with Hepatocellular Cancer and Low Blood Levels of sTWEAK are Associated with Poor Survival". Uluslararası Hematoloji-Onkoloji Dergisi 27/2 (2017), 118-126.